Oxymorphone Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Oxymorphone stocks.

Oxymorphone Stocks Recent News

Date Stock Title
May 14 DRRX Q1 2024 DURECT Corp Earnings Call
May 14 DRRX Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...
May 14 DRRX DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript
May 13 DRRX Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
May 13 DRRX DURECT GAAP EPS of -$0.25 misses by $0.03, revenue of $1.83M misses by $0.9M
May 13 DRRX DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
May 13 COLL Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13 COLL Collegium announces $35 million accelerated share repurchase program
May 13 COLL Collegium Announces $35 Million Accelerated Share Repurchase Program
May 12 DRRX DURECT Q1 2024 Earnings Preview
May 10 COLL Collegium downgraded by Piper Sandler over valuation
May 10 COLL Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet
May 9 COLL Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript
May 9 COLL Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 9 COLL Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
May 9 COLL Collegium announces CEO Joe Ciaffoni to step down
May 9 COLL Collegium Pharmaceutical Non-GAAP EPS of $1.45 misses by $0.02, revenue of $144.9M misses by $2.04M
May 9 COLL Collegium Reports First Quarter 2024 Financial Results
May 9 COLL Collegium Announces CEO Transition
May 8 COLL Collegium Pharmaceutical Q1 2024 Earnings Preview
Oxymorphone

Oxymorphone, sold under the brand names Numorphan among others, is a powerful semi-synthetic opioid analgesic (painkiller) developed in Germany in 1914. Pain relief after injection begins after about 5–10 minutes and 15–30 minutes after rectal administration, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets.It is highly addictive and in June 2017 the FDA asked the manufacturer to remove its product from the US market. This was in part due to the opioid epidemic in the US, and the fact that the 2012 reformulation led to a shift in the route of abuse from nasal to injection. It was the first time in the history of the agency, that the FDA had made a request for removal regarding a product currently on the market. In response, by July 2017, Endo International voluntarily removed Opana ER from the market. Generic versions of extended release oxymorphone are still available for prescription use in the US.

Browse All Tags